NCT06690047View on ClinicalTrials.gov

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL

Ruconest

recombinant human C1-esterase inhibitor

Trial Locations (2)

35209

Clinical Research Center of Alabama, Birmingham

45236

Bernstein Clinical Research Center, LLC, Cincinnati

Sponsors
All Listed Sponsors
lead

Bernstein Clinical Research Center

OTHER